
Nanomedicine, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 4
Published: Dec. 27, 2024
KEYWORDS: Brain deliveryblood-brain barrierbioactive compoundsnanoparticlesbrain targetingneurodegenerations
Language: Английский
Nanomedicine, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 4
Published: Dec. 27, 2024
KEYWORDS: Brain deliveryblood-brain barrierbioactive compoundsnanoparticlesbrain targetingneurodegenerations
Language: Английский
PLoS ONE, Journal Year: 2025, Volume and Issue: 20(2), P. e0316389 - e0316389
Published: Feb. 28, 2025
Depression poses a significant global health challenge, affecting an estimated 300 million people worldwide. While amitriptyline (Ami) remains one of the most effective antidepressants, its numerous side-effects contribute to high dropout rate among patients. Addressing this issue requires exploring methods enhance bioavailability and reduce dosage. In study, we describe technique for producing nanoparticles (Ami-NPs) improve drug’s efficiency. The effectiveness was assessed by comparing dose-response curves Ami-NPs non-encapsulated Ami in male female Wistar rats subjected forced swimming test (FST). were fabricated using nanoprecipitation, with copolymer poly (methyl vinyl ether/maleic acid) as encapsulant, 3% solution poloxamer F-127 surfactant stabilizer. A Box-Behnken design used optimize production Ami-NPs, resulting following optimal characteristics: size 198.6 ± 38.1 nm, polydispersity index 0.005 0.03 zeta potential -32 6 mV, encapsulation efficiency 79.1 7.4%. showed higher potency efficacy reducing immobility during FST (ED 50 = 7.06 mg/kg, E max 41.1%), compared (Ami-S) 11.89 33.2%). occurred at 12 while Ami-S peaked 15.8 mg/kg. open field test, only treatment (12 mg/kg) empty increased immobility. elevated plus-maze, significantly reduced closed-arm entries (2.1 0.6), control (9.5 1.8), (8 1.0) (11.5 2). marble burying buried marbles (2.4 0.4) (8.7 1.2). These findings suggest that could be promising approach bioavailability, thereby increasing antidepressant efficacy, improving anxiolytic-like effects.
Language: Английский
Citations
0Nanomedicine, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 4
Published: March 15, 2025
Language: Английский
Citations
0Colloids and Surfaces B Biointerfaces, Journal Year: 2025, Volume and Issue: unknown, P. 114655 - 114655
Published: March 1, 2025
Language: Английский
Citations
0Computational and Structural Biotechnology Journal, Journal Year: 2025, Volume and Issue: unknown
Published: March 1, 2025
Tumor necrosis factor (TNF) receptor 1 (TNFR1) plays a central role in signal transduction mediating inflammation and cell death associated with autoimmune neurodegenerative disorders. Inhibition of TNFR1 signaling is highly sought-after strategy to target these diseases. forms pre-ligand dimers held together by the assembly domain (PLAD), which essential for signaling. form crucial points interaction entire complex connecting TNF ligand bound trimeric receptors. While previous studies have shown feasibility disrupting dimeric interactions through competitive mechanism that targets PLAD, our recent demonstrated small molecules could also bind PLAD modulate an allosteric mechanism. Importantly, modulators alter dynamics propagate long-range conformational perturbation involves reshuffling receptors cytosolic domains without receptor-receptor or receptor-ligand interactions. In this study, we perform molecular docking previously reported on extracellular understand their binding sites interacting residues. We identify inter-monomeric space between as novel pocket modulators. further conduct pharmacological analyses bioactivity compounds residues properties. then provide insights into structure-activity relationship targeting dynamics. This paves way developing new therapeutic strategies designing chemical scaffolds
Language: Английский
Citations
0International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 5893 - 5905
Published: May 1, 2025
The blood-brain barrier (BBB) is a critical protective that regulates the exchange of substances between circulatory system and brain, restricting access drugs to brain tissues. Developing novel delivery strategies across BBB challenging but crucial. Multifunctional nanogels are promising drug carriers for delivering therapeutic agents their intended target areas in tissue. This study introduced carboxylic acid- amine-modified Pluronic F127 (ADF127 EDF127)-based thermoresponsive nanogel systems as nanocarriers release profiles 3-butylidenephthalide (BP) from were investigated vitro phosphate-buffered saline (pH 7.4) at 37 °C 48 h. Additionally, accumulation DiR-labeled vital organs was observed using fluorescence imaging. A relatively sustained BP (27%) ADF127, followed by rapid (39%) within first 4 h observed. In vivo studies C57BL/6JNarl mouse model showed intravenously administered BP-loaded copolymeric exhibited distribution liver, spleen, heart, kidney. DiR intensity increased order < ADF127 EDF127 nanogels. Although tissue lower than those other organs, approximately 10-fold higher intensity. Positively charged carrier nanomaterials demonstrate propensity transfer through BBB, significantly expanding applicability positively treatment Therefore, owing permeability (EDF127 ADF127) will also offer approach
Language: Английский
Citations
0Deleted Journal, Journal Year: 2025, Volume and Issue: unknown
Published: May 7, 2025
Language: Английский
Citations
0Nanomaterials, Journal Year: 2025, Volume and Issue: 15(10), P. 704 - 704
Published: May 8, 2025
Intrinsically disordered proteins (IDPs), such as tau, beta-amyloid (Aβ), and alpha-synuclein (αSyn), are prone to misfolding, resulting in pathological aggregation propagation that drive neurodegenerative diseases, including Alzheimer’s disease (AD), frontotemporal dementia (FTD), Parkinson’s (PD). Misfolded IDPs aggregate into oligomers fibrils, exacerbating progression by disrupting cellular functions the central nervous system, triggering neuroinflammation neurodegeneration. Furthermore, aggregated exhibit prion-like behavior, acting seeds released extracellular space, taken up neighboring cells, have a propagating pathology across different regions of brain. Conventional inhibitors, small molecules, peptides, antibodies, face challenges stability blood–brain barrier penetration, limiting their efficacy. In recent years, nanotechnology-based strategies, multifunctional nanoplatforms or nanoparticles, emerged promising tools address these challenges. These leverage tailored designs prevent remodel reduce associated neurotoxicity. This review discusses advances designed target Aβ, αSyn aggregation, with focus on roles reducing We examine critical aspects nanoplatform design, choice material backbone targeting moieties, which influence interactions IDPs. also highlight key mechanisms interaction between inhibit redirect cascade towards nontoxic, off-pathway species, disrupt fibrillar structures soluble forms. further outline future directions for enhancing IDP clearance, achieving spatiotemporal control, improving cell-specific targeting. nanomedicine strategies offer compelling paths forward developing more effective targeted therapies diseases.
Language: Английский
Citations
0Biomedicine, Journal Year: 2024, Volume and Issue: 14(4)
Published: Dec. 1, 2024
Introduction: Our previous research demonstrated that a large language model (LLM) based on the transformer architecture, specifically MegaMolBART encoder with an XGBoost classifier, effectively predicts blood-brain barrier (BBB) permeability of compounds. However, coefficients compounds can traverse this remain unclear. Additionally, absorption, distribution, metabolism, and excretion (ADME) characteristics substances obtained from Natural Product Research Laboratory (NPRL) at China Medical University Hospital (CMUH) have not yet been determined.
Language: Английский
Citations
1International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(23), P. 12883 - 12883
Published: Nov. 29, 2024
MicroRNAs (miRNAs) maintain cellular homeostasis by blocking mRNAs binding with them to fine-tune the expression of genes across numerous biological pathways. The 2024 Nobel Prize in Medicine and Physiology for discovering miRNAs was long overdue. We anticipate a deluge research work involving repeat history prizes awarded on other RNAs. Although miRNA therapies are included several complex diseases, realization that regulate their roles addressing hundreds diseases expected; but advancement drug discovery tools, we even faster entry new drugs. To promote this, provide details current science, logic, intellectual property, formulations, regulatory process anticipation many more researchers will introduce novel based discussion advice provided this paper.
Language: Английский
Citations
1Biomaterials, Journal Year: 2024, Volume and Issue: 316, P. 123021 - 123021
Published: Dec. 15, 2024
Language: Английский
Citations
1